Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management (FE-Compatible plans) | Covered with PA |
| Obesity / weight management (standard commercial plans, non-formulary, exception required) | Not covered |
| Obstructive sleep apnea (SURMOUNT-OSA indication, FE-Compatible plans) | Covered with PA |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. Self-funded employers set their own formularies and can elect to retain Zepbound coverage regardless of the CVS Caremark standard formulary decision. Two employees with identical Aetna cards at different companies may have different Zepbound coverage. Check your summary of benefits or call the number on your card.
Coverage by indication
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, or cardiovascular disease) |
| Step therapy | No step therapy through other agents is specified in policy 6947-C for FE-Compatible plans. |
| Continuation | At least 5 percent loss of baseline body weight within the first 3 months of therapy |
| Authorization length | 8 months initial, 12 months continuation |
What the prior authorization needs:
- FE-Compatible plan type is required; this policy does not apply to standard commercial plan series (ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC)
- Documented BMI within the accepted threshold
- Six months of structured weight-management program participation (behavioral modification, reduced-calorie diet, increased physical activity)
- Comorbidity documentation if BMI is 27 to 29.9
Policy 6947-C P04-2025. Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound PA with Limit FE Compatible 6947-C P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
On standard commercial plan series (ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC), Zepbound is non-formulary for weight loss since July 1, 2025. A formulary exception under policy 6981-A requires documented step-through of Wegovy (semaglutide 2.4 mg injection) before Zepbound can be approved. If Wegovy is contraindicated or not tolerated, an exception may be granted without step-through. CVS Caremark removed Zepbound from its Standard, Advanced Control, and Value formularies, affecting an estimated 200,000 patients. The Massachusetts Office of Health and Human Services documented the removal publicly.
| Effective date | 2025-07-01 |
Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound Exception Policy 6981-A P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Moderate to severe OSA, AHI 15 or more obstructive respiratory events per hour confirmed by polysomnography or home sleep apnea test |
| Authorization length | 6 months initial, 12 months continuation (requires documented positive treatment response with decreased OSA symptoms) |
What the prior authorization needs:
- FE-Compatible plan type required
- Established diagnosis of moderate to severe OSA with AHI 15 or higher
- BMI 30 or higher
- Concurrent reduced-calorie diet and increased physical activity
- Documented positive treatment response required for continuation
Policy 6947-C P04-2025. Source: Aetna Non-Medicare Prescription Drug Plan, Zepbound PA with Limit FE Compatible 6947-C P04-2025 (effective July 1, 2025). Official payer PA policy page (HTML). Verified June 18, 2026.
Recent change: CVS Caremark, Aetna's pharmacy benefit manager, removed Zepbound from standard formularies effective July 1, 2025, citing a negotiated pricing deal with Novo Nordisk (Wegovy's manufacturer). Wegovy became the preferred covered weight-loss GLP-1. CVS Caremark confirmed no additional GLP-1 formulary changes for 2026. Self-funded employer plans were not bound by this decision and may retain Zepbound coverage.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does Aetna cover Zepbound?
It depends on your plan type. Aetna removed Zepbound from its standard commercial formularies for weight loss effective July 1, 2025, after CVS Caremark (Aetna's pharmacy benefit manager) dropped it from standard formularies. On FE-Compatible plan types, Zepbound is still covered with prior authorization. On standard commercial plan series, Zepbound is non-formulary and requires a formulary exception with Wegovy step-through. This reflects the published policy verified June 2026.
What does Aetna require to approve Zepbound?
For obesity / weight management (FE-Compatible plans): The BMI requirement is BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, or cardiovascular disease). No step therapy through other agents is specified in policy 6947-C for FE-Compatible plans. Authorization runs 8 months initial, 12 months continuation.
Why might Aetna deny Zepbound even if I meet the criteria?
Self-funded employers set their own formularies and can elect to retain Zepbound coverage regardless of the CVS Caremark standard formulary decision. Two employees with identical Aetna cards at different companies may have different Zepbound coverage. Check your summary of benefits or call the number on your card.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
